Materialise N.V. (MTLS) Q3 2019 Earnings Report, Transcript and Summary

Good morning, ladies and gentlemen, and welcome to the Materialise Third Quarter Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the conference over to your host, Ms. Harriet Fried of LHA.

Thank you for joining us today for Materialise’s quarterly earnings call. With us on the call are Fried Vancraen, Founder and Chief Executive Officer of Materialise; Peter Leys, Executive Chairman; and Johan Albrecht, Chief Financial Officer. Today’s call and webcast are accompanied by a slide presentation that reviews Materialise’s strategic, financial and operational performance for the third quarter of 2019. To access the slides if you’ve not already done so, please go to the Investor Relations section of the Company’s website at www.materialise.com. The earnings release issued today can also be found on that page. Before we begin, I’d like to remind you that management may make forward-looking statements regarding the Company’s plans, expectations and growth prospects, among other things. These forward-looking statements are subject to known and unknown uncertainties and risks that could cause actual results to differ materially from the expectations expressed, including competitive dynamics and industry change. Any forward-looking statements, including those related to the Company’s future results and activities, represent management’s estimates as of today and should not be relied upon as representing their estimates as of any subsequent day. Management disclaims any duty to update or revise forward-looking statements to reflect future events or changes in expectations. A more detailed description of the risks and uncertainties and other factors that could impact the Company’s future business or financial results can be found in the Company’s Annual Report on Form 20-F filed with the SEC. Finally, management will discuss certain non-IFRS measures on today’s call. A reconciliation table is contained in the earnings release and at the end of the slide presentation. With that introduction, I’d like to turn the call over to Peter Leys. Go ahead, please, Peter.

Thank you, Harriet, and thank you, everyone, for joining us today for our call. As always, you will find the agenda for today on Slide 3. On the right, you will see the picture of three gentlemen who have not changed over the last four years since we started using the slides. And on the left, you will find the agenda, which frankly hasn’t changed much either. As always, we’ll begin with a brief recap of our results for the quarter, then Fried as always will come on, and this time Fried will discuss some of the strategic and technological drivers for the continued success of Materialise Software. After Fried, you will hear Johan who will go through our third quarter numbers in more detail and then I’ll come back on to review our financial guidance for the rest of the year. And when we’ve completed our prepared remarks, we will be happy to respond as always to any questions that you may have. So turning to Slide 4, you will see the highlights of our third quarter results. Now despite macroeconomic environment that remains challenging, Materialise continues to grow. Our total revenue as you saw rose 8%. You realized a quarterly adjusted EBITDA record of more than €8 million this quarter and we generated €1 million of net profits. Importantly, Materialise Software enhance its performance in Q3 significantly as we forecasted in our Q2 call. With a revenue growth of 10% and an EBITDA margin that came back to normal of 35%. Also Materialise Medical performed very well. We believe with revenues growing 21% quarter-over-quarter and with an EBITDA margin of 18%, including the August, September results of Engimplan. And finally Materialise Manufacturing also grew its EBITDA margin to a solid 16% and this on the back of stable revenues that grew modestly by roughly 0.5%. Against that background, I would like to turn the call now over to Fried, who will among other things, expands on our software strategy. Fried, go ahead.

Thank you, Peter. Good morning, and good afternoon, to everyone. Thank you for joining us today. While we are heading fast to the big [indiscernible] of the 3D printing industry at Formnext in Frankfurt starting November 19. I would like to use the opportunity of this quarterly call to give an update on the Materialise Software strategy. Our strong Q3 software results demonstrated Materialise Software tools remain the productivity drivers for the majority of the professional 3D printer users. At Formnext, we will introduce several new upgrades of our products that increase productivity further. These tools have been built along two major access. Firstly, our development teams have come up with solutions that dramatically increase the speed at which our tools can process data. For 3D nesting a crucial to make selective laser sintering and Multi-Jet Fusion technology is more cost effective. Our development teams managed to increase the processing speed by whopping factor of 30. Importantly, customers can translate it amazing increase in data processing speed directly into productivity gains. As you know, as printed parts become more and more complex, build platforms become larger and larger, and packing becomes more and more dense. As a result, the associated data files increased significantly in size, which impacted the time that is required to process the data that must be important into the machines. In certain environments, the ability to process data significantly faster and just keep the data preparation time as short as possible becomes a major driver to increase the productivity of 3D printing facility. That is exactly what our newest generation of nesting tools do. In addition to saving time, our highly efficient nesting also saves power, which decreases both the production cost and the environmental impact of the 3D printing process. Secondly, the new generation of products include significant enhanced automation functionalities. Automation is particularly important for environments where customized product or wide varieties of different parts are made. In these situations, the work planning is a major cost factor and automation saves considerable working out of the people that are involved in the planning process. Very importantly, from a software architecture perspective, our new product releases are based on a set of internally developed underlying software API that allow us to integrate new functionality seamlessly with existing functionalities that have been fine tuned and stabilized within Materialise for over 30 years of software development. These APIs operate both in our cloud based solutions and on distributed devices. If new generation of APIs will allow us to significantly shorter the time to market of new functionalities that we are currently already testing within our own end part production. All those new software tools will be addressing the major hurdle that the 3D printing industry is facing today. The transition to real manufacturing of end products, this transition has been going slower than many market watchers and consultants initially predicted. One of the major reasons is that it takes much more effort and most engineers ever estimated to make the transfer from a product development environment, we are just one, prototype is printed, two, genuine manufacturing environment where many end parts are printed consistently and reliably over a long period of time. Take the same as example of the GE fuel nozzle that took multiple years of new product introduction or NPI process before it could really be launched in commercially successful circumstances. This same painstaking NPI process happens over and over again for every new application of a 3D printed end part. Within our own production, we witnessed it for multiple meaningful applications in different sectors such as healthcare, aerospace, automotive, and variables. Based on this painstaking experience within Materialise, we have developed a new suite of NPI software products that are all built on a new Materialise score API and that will help that new product introduction of 3D printed parts significantly. I was glad to compare the use of the APIs within Materialise Software with the introduction of scripting within Materialise Medical segments, approximately two years ago. Scripting allowed our Medical segment to accelerate the development of new planning and design tools to the benefit of many companies dealing with patient specific data. Just as scripting contributed to the good growth numbers of software sales with our Medical segment, we expected a new generation of APIs can contribute similarly to the continued growth of our Software segment. Let me conclude by stating that for Materialise, Formnext will also be again a celebration of the partnerships. Partnerships we have with many players in the 3D printing industry, machine manufacturers, material manufacturers, and of course, the key course – the key users of additive manufacturing technologies. A good example of various partnerships that come together in the commercial launch of the new TPU material from BASF on the HP, MJF printers within Materialise Manufacturing in September. At this point, Johan will come on to give you more details on our third quarter financial results.

Thank you, Fried. I’ll begin with a brief review of our consolidated revenue on Slide 6. As a reminder, when we refer to sales in our presentation, we mean revenues plus deferred revenues. Also, please note that unless otherwise stated all comparisons in this call are against our results for the third quarter of 2018. As Peter mentioned in his opening remarks, in this year’s third quarter, we generated an 8% increase in revenue driven by our Medical segment and an acceleration of sales performance in our Software segment, which returned to double-digit growth. Deferred revenue from annual software sales and maintenance contracts increased €1.4 million compared to year end 2018. For the quarter, Materialise Software accounted for 21% of our total revenue, Materialise Medical for 31% and Materialise Manufacturing for 48%. Cross-segment revenue from software products accounted for 31% of our total revenue. Moving to Slide 7, you will see our consolidated adjusted EBITDA numbers for the third quarter. Consolidated adjusted EBITDA increased almost €1 million, from €7 million to €8 million. Our EBITDA margin increased from 15.1% to 15.9%. Unlike the previous period, the third quarter 2019 EBITDA included a positive effect of €632,000, resulting from the new IFRS 16 Accounting Standard that requires us to capitalize certain lease expenses as of 2019. This new accounting standard has little impact on our operating profit, as depreciation expenses increased by the same amount. Improved gross margin and moderate increase of operating expenses resulted in 25% increase our operating profit. Slide 9 summarizes the results of our Materialise Software segment. Here, revenue grew by 10% or almost €1 million. The rebound from the softer first half of the year was reflected in Q3 sales growth of 16.4%. Recurring revenue was up 5.3%. Non-recurring revenue was up 14.4%, boosted by OEM sales. The segment’s EBITDA increased to €3.8 million from €3.4 million in last year’s quarter. The EBITDA margin also increased to almost 35%, despite the continued expansion of our software sales and marketing capacity. Moving now to Slide 9, you will see the total revenue in our Materialise Medical segment grew 21% for the quarter to €15.5 million. Revenue from Medical Device solutions rose 25%, accounting for 68% of the total segment’s revenue. This quarter’s report includes the results of the Engimplan acquisition that we consolidated since the 1 of August 2019. As Engimplan manufactures and sells orthopedic and cranio-maxillofacial, CMF implants and instruments, its revenues are reported under Medical Device solutions. Engimplan’s August and September 2019 revenues amounted in the aggregate to €1,029,000. Excluding Engimplan, total revenue from Materialise Medical still grew by a very solid 12.7% and medical devices and services revenue grew by 12.8%. Revenue from our medical software, which accounted for 32% of the segment’s revenue, which was not impacted by the Engimplan acquisition grew equally strongly by 12.7%. EBITDA for the Medical segment was €2.8 million compared to €2.5 million. The EBITDA margin was 18% as compared to 19%. Now let’s turn to Slide 10, for an overview of the Q3 performance of our Materialise Manufacturing segment. Their revenue was up by 0.5%, reflecting a small increase in both our traditional manufacturing and ACTech businesses. In light of the soft macroeconomic environment, we think this is a good performance. EBITDA rose 13% resulting in an EBITDA margin of 16%, the solid EBITDA grew in the context of a low top line growth reflects the results of our continuous efforts to improve operational excellence. In the third quarter of 2019, we added one printer as compared to the previous quarter, which brings the total amount of printers that we have in production in our Manufacturing and Medical segments to 193. Slide 11 provides the highlights of our income statement for the third quarter. Revenue rose 8% and gross profit rose 10% compared to last year’s period. In total, sales and marketing, G&A and R&D spending rose by 11.2% over the prior year period. Sales and marketing rose 20%, mainly by continued capacity expansion in our Software and Medical segments. G&A increased 7% and R&D was split. This R&D cost excludes expenditures in Q3 2019 of €301,000 that were capitalized as intangible assets from the tracheal splint initiative. In total, the intangible assets related to the development initiatives amounted to €1,480,000 on our balance sheet at the end of the third quarter 2019. Net other operating income increased by €760,000 to €1.3 million compared to €600,000. As a result of all these amounts, the group’s operating profit increased 25% to €2.9 million compared to €2.3 million. The net financial result was negative €966,000 compared to a positive €268,000 last year. The decrease primarily reflects the negative exchange rate variances that were particularly positive in last year’s period. To a minor extent, the interest on the European Investment Bank drawing of €25 million has also a negative impact on the financial results. Income tax amounted to €908,000 compared to €230,000 in the third quarter 2018, in this quarter, it’s includes a negative variance in deferred income tax of €466,000. Net profit for the third quarter was €1,001,000 compared to €2,316,000 for the same period in 2018. Net profit for the quarter includes the 25% non-controlling interest profit of €72,000 related to Engimplan. Now please turn to Slide 12 for a recap of balance sheet and cash flow highlights. Our balance sheet remains strong with cash of €131.1 million compared to €115.5 million as of December 31 last year. The increase of cash reflects the strong EBITDA performance focus on reducing accounts receivable and the drawing of the second tranche of €25 million from a credit facility with the European Investment Bank, partly offset by other loan reimbursements, the Engimplan acquisition and other capital expenditures and the payment of the €2.5 million convertible loan that we extended in Q1 Fluidda and that we referred to in one of our previous earnings calls. The Engimplan acquisition was paid using our U.S. dollar proceeds. Total debt rose €25.6 million from year-end 2018 to $131.6 million, besides the €25 million tranche drawn by the European Investment Bank, this debt also includes €4.9 million of total lease liabilities from the new accounting standard IFRS 16 and €1.3 million debt from the Engimplan acquisition. Capital expenditures for the quarter amounted to €5.6 million of which less than 20% was financed. This amount includes the €301,000 capitalized development costs for the medical project explained earlier. Cash flow from operating activities for the quarter increased to a new quarterly records of €13.8 million compared to €7.2 million in Q3 last year. This is the result of the combination of a strong EBITDA and working capital improvements of €6.6 million this quarter. Total deferred revenue amounted to €29.4 million as compared to €27.8 million as of end last year. Of the €29.4 million, €24 million were related to annual software sales and maintenance contracts versus €22.6 million as of end last year. With that overview, I’ll turn the call back to Peter.

Thank you, Johan. I wanted to conclude our prepared remarks this morning by touching briefly on our financial guidance for the rest of the year. As you may remember, last quarter we confirmed our targets for the full year albeit at the lower end of the range with respect to EBITDA. As we explained last time, this was based on our view that our Medical and Manufacturing segments would continue to do well and that our software segment would do significantly better than the first half of 2019. Our sales teams lived up to these high expectations in Q3 and you would like to congratulate them for that. As we’ve just discussed, overall revenues grew by 8% and including because of the strong performance of our software sales Materialise turned in a record quarterly EBITDA of more than €8 million. Still, to reach our full year targets, we will need to exceed the already excellent results of Q3 in the current quarter Q4. Our strong showing in the third quarter and our pipeline for the remainder of the fourth quarter, which is traditionally our strongest period, show that this is indeed possible even in the soft macroeconomic environment that we live in today. Provided however, that we fully include the EBITDA contribution by Engimplan in the fourth quarter that our Manufacturing segment does not experience any unexpected downward swing and that our software sales include the high level of recognizable revenue for Q4 that we currently expect. While the key driver for EBITDA generation within Materialise remains top line growth, we also expect some positive contribution from the continuous improvement programs that we have launched within our organization. And with this, we would like to conclude our prepared remarks. So operator, we are now ready to open the call to questions.

[Operator Instructions] Your first question comes from the line of Troy Jensen with Piper Jaffray.

Hey gentlemen, congrats on the nice results.

Thank you, Troy.

Thank you.

Hey Peter, for you, it sounds like is the most convictions coming from is software growth, right, when you look at kind of Q4 forecast here. So just be curious if you can dive in a little bit. Is it the traditional 3D software versus 3D healthcare? Is it OEM partners that are really ramping? Or is it these a new generation of APIs that Fried mentioned in his prepared remarks that are given you guys that kind of confidence.

The software growth that I refer to Troy, first and foremost to the sales of our traditional software tools that are sold within our Software segment. But I would like to add, and we – where we touched upon that during the prepared remarks that we’ve seen a fairly strong rebound of our OEM sales, which were soft in the first half of the year. They were much stronger in Q3 and we expect that they will continue to contribute in Q4 and that they will continue to help us continue the trend of growing sales within the Software segment in Q4. That being said, we will need all the help we can in Q4 and we also expect that the medical software sold within our Medical segment will also contribute to what we expect to be a good solid and strong fourth quarter. Now the APIs a new product introduction tools that Fried refer to, they will not contribute to our top line in Q4. If anything they explain for a part our continued investment in R&D, but they are exciting because they show that we are just not relying on the successful products that we have been relying on for such a long time that we are revamping and actually making that software backbone fully ready for the next generation of end parts production applications.

So then maybe for Fried, just to piggyback of Peter’s comments on the strength in the OEM partners for software sales. I’m assuming that’s production applications and be curious to know kind of what Materialise is also seeing in their manufacturing for kind of more of a effort to get a growth in production?

Well, first of all, like Peter said, the tools we are currently selling or mostly the – yes, legacy products of Materialise all by they’re used more and more for production applications, especially on the metal side. We also see in our own reduction that there is increase demand for metal production components where prototyping is playing a much smaller role. But if Materialise can maintain a steady position, at this moment in the soft climate, it is mostly because the growth of certified manufacturing in our manufacturing operations. So this is showing that this transition to end part manufacturing continues.

And how about Fried, I’d love to get your thoughts to on just a European automotive vertical. Have we bottomed here given kind of coming out of Q3 now, is there any improve visibility kind of go into next year with a European auto?

Well, it remains – let’s say a difficult answer, a different – difficult question to answer. At this moment, there are quite some raise of hope that the situation will improve, especially in product development for the automotive sector, although the exact timing of that rebound is still questionable. And definitely as what we are currently generating in revenues in Q4 is based on what was sold before. The impact of the automotive sector in Q4 will still be really, yes – bad. But for next year there is hope, many levels that the situation will improve. But we don’t know whether did this start will be as of the beginning of the year or the second quarter or only the second half of the year. That’s still very cloudy.

Right, appreciate it. I have a just last question from me within medical, I’m assuming these roughly stable and most of the growth is coming from CMF and some of the new applications.

That’s correct.

Yes.

Same trends as previous quarters.

Great. Well, perfect. Congrats again, guys, and good luck in Q4.

Thank you, Troy.

Thank you.

[Operator Instructions] Your next question comes from the line of Jason Celino with KeyBanc Capital Markets.

Hi, guys. How’s it going?

Hey, Jason.

Just a couple of questions for me. First question, it looks like Engimplan contributed a little bit under €2 million for the medical revenue. Is that correct? Or – and then, I know it’s still early, but what it’s been early feedback like since you both have come together.

So the revenue, this was contributed in Q3 over the two months of August and September, when we started consolidating 1st of August is €1,029,000.

Yes. And the operational level of course these are the first month now that we are collaborating. We are very happy with the positive mindset and the results of our new colleagues in Brazil. But let’s say, and this is a medical sector to integrate the product portfolios of Materialise into the Brazilian market and the other way around will take us approximately one year, because of all the regulatory hurdles that need to be met.

Got it, great. And then thinking about the steps you’re taking throughout your organization to maximize effectiveness. Maybe can you talk about what some of those steps are and how those are going?

It’s – I mean, we haven’t launched any particular or specific program, James. It’s just that we – as these are difficult and uncertain times, where from a growth perspective, we are doing well. We are keeping an eye on our cost base and are making today even more shorter than we did yesterday, that the dollar that we do spend are spent for the right verticals and for the right initiatives. So it’s more a matter of being even more focused and disciplined than anything else without losing, of course, sites of the growth drivers that we have identified and that we will continue to invest in.

And I want to add to that, of course, our operational costs and especially our 3D printing cost is something where we work on continuously to improve the productivity of our machines and which is the basis for our software tool development.

Okay, great. And last question, actually, if I could just build off of Troy’s question, in the auto OEMs in Europe, relative to maybe a quarter ago, would you describe maybe no change in overall condition or any incremental commentary you’d like to add?

Well, the key element why some of the developments are not growing faster, remains the uncertainty about the regulatory climate for the new generations of both cards that exist, and there many people in the auto sector hope that some clear decisions will be made by the different governments and by the European union with regard what the new emission standards and so on will be this holding back some of the developments.

Okay, great. I appreciate the color. Thank you.

Thank you.

Your next question comes from the line of Gregory Ramirez with Bryan Garnier.

Yes, thank you. Good afternoon. Just maybe more clarification and the question, it’s related to your guidance for the full year. You mentioned that it will be at the lower end of the range. After Q2, you mentioned only, it will be at the low end of the range for EBITDA – adjusted EBITDA exceeding Engimplan. Now, does your guidance includes Engimplan and do we have also to expect that the low end of the guidance applies to revenues as well, that is to say that total revenues include the Engimplan will be more towards €196 million and €204 million. Thank you.

Thank you, Greg for this question and it will allow us to take away any doubts if there will be any. We maintain that, when we guide towards the lower end of the initial range that relates to EBITDA. As I said in the prepared remarks, the biggest EBITDA generator within Materialise is still our revenue growth. So the main caution really relates to the range for EBITDA and not as much to the deferred revenue range that we provided nor more importantly to the recognized revenue range that we provided. The second part, Greg, of your question, I think related to Engimplan. Definitely in last call, we were still hopeful that we would be able to use the Engimplan contribution to our EBITDA as a kind of safety buffer, let’s say. To help us meet the bottom of the range, it’s €29 million. If you’re listening carefully to our prepared remarks now we really – fully also rely on the full contribution by our friends in Rio Claro in Brazil to allow us to get to that bottom end or lower end of the EBITDA range.

Okay, great. Thank you very much.

Sure. You’re welcome.

I’m showing no further questions at this time. I would now like to turn the conference back to Peter Leys.

Thank you. Thank you operator, and thank you all for joining us today. As Fried already mentioned earlier for next, it’s coming up in the week of November 2019. So we very much look forward to being there and what a particular we look forward to meeting some of you in the course of those three to four days. Thank you all and enjoy the rest of the day and the week. Bye.

Goodbye.

Goodbye.

Ladies and gentlemen, this concludes today’s conference. Thank you for your participation and have a wonderful day. You may all disconnect.